G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize ...
Pfizer reported that its ultra-long-acting, once-monthly GLP-1 injectable achieved up to 12.3% placebo-adjusted weight loss ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses ...
I think it has both implications for the civilian setting, particularly in longer transport or resource-limited areas," Dr. Adit Ginde said.
Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11 ...
Individual-level attribution modeling reveals that real-world semaglutide effectiveness is not a fixed property of the molecule, but an interaction between pharmacological exposure and modifiable care ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its ...
Ozempic and similar weight loss drugs offer major benefits for obesity and heart health, but side effects, muscle loss, and ...
A phase 3 trial of ferric citrate supports its use as a treatment for iron deficiency anemia in non-dialysis chronic kidney disease (CKD).
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended1Results favored Vanrafia across multiple ...
US pharma giant Pfizer today announced positive top-line results from the Phase IIb VESPER-3 study investigating monthly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results